Skip to main content
logo
Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
308.43
+2.89 (0.95%)
Apr 27, 2026, 12:27 PM EDT - Market open

Alnylam Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
3,7142,2481,8281,037844.29
Revenue Growth (YoY)
65.19%22.97%76.23%22.88%71.31%
Cost of Revenue
681.87323.37310.41168.82140.14
Gross Profit
3,0321,9251,518868.6704.14
Selling, General & Admin
1,211975.53795.65770.66620.64
Research & Development
1,3201,1261,004883.02792.16
Total Operating Expenses
2,5302,1021,8001,6541,413
Operating Income
501.58-176.89-282.18-785.07-708.65
Interest Income
111.47121.9995.5624.811.58
Interest Expense
-252.63-141.86-121.22-155.97-143.02
Other Non-Operating Income (Expense)
-37.27-180.62-125.68-210.76-2.05
Total Non-Operating Income (Expense)
-178.43-200.49-151.34-341.92-143.49
Pretax Income
323.15-377.38-433.52-1,127-852.14
Provision for Income Taxes
9.41-99.226.734.160.68
Net Income
313.75-278.16-440.24-1,131-852.82
Net Income to Common
313.75-278.16-440.24-1,131-852.82
Shares Outstanding (Basic)
131128125122118
Shares Outstanding (Diluted)
135128125122118
Shares Change (YoY)
5.51%2.20%2.64%2.73%3.01%
EPS (Basic)
2.39-2.18-3.52-9.30-7.20
EPS (Diluted)
2.33-2.18-3.52-9.30-7.20
Shares Outstanding
132.38129.29125.79123.93120.18
Free Cash Flow
465.38-42.5941.95-613.33-718.07
Free Cash Flow Per Share
3.46-0.330.34-5.04-6.06
Gross Margin
81.64%85.62%83.02%83.73%83.40%
Operating Margin
13.51%-7.87%-15.43%-75.68%-83.94%
Profit Margin
8.45%-12.37%-24.08%-109.04%-101.01%
FCF Margin
12.53%-1.89%2.29%-59.12%-85.05%
EBITDA
557.24-120.22-228.12-740.6-661.09
EBITDA Margin
15.00%-5.35%-12.48%-71.39%-78.30%
EBIT
501.58-176.89-282.18-785.07-708.65
EBIT Margin
13.51%-7.87%-15.43%-75.68%-83.94%
Effective Tax Rate
2.91%26.29%-1.55%-0.37%-0.08%
Updated Feb 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q